{"id":"cord-blood-cell","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection at transplant site"},{"rate":null,"effect":"Immune rejection"},{"rate":null,"effect":"Pain at injection site"},{"rate":null,"effect":"Neurological complications"}]},"_chembl":null,"_dailymed":{"setId":"4e9b6da8-2614-4dea-8d43-a8ef3e1d1f46","title":"HEMATOPOIETIC PROGENITOR CELLS, CORD BLOOD (HUMAN CORD BLOOD HEMATOPOIETIC PROGENITOR CELL) LIQUID [CLINIMMUNE LABS, UNIVERSITY OF COLORADO BLOOD BANK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cord blood cells, typically hematopoietic stem cells or other progenitor cells, are transplanted into the injured spinal cord where they may differentiate into neural cells, secrete neurotrophic factors, and modulate the inflammatory microenvironment. This multi-modal approach aims to restore lost neural tissue, protect surviving neurons, and promote axonal regeneration and functional motor/sensory recovery.","oneSentence":"Cord blood-derived cells promote neural regeneration and functional recovery in spinal cord injury through cell replacement, neuroprotection, and anti-inflammatory effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:59:40.696Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Spinal cord injury"}]},"trialDetails":[{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT07444632","phase":"PHASE1","title":"Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":"Lymphoid, Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT03173937","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-06-13","conditions":"Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)","enrollment":37},{"nctId":"NCT07492628","phase":"PHASE1","title":"Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-03-02","conditions":"Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":42},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT07332338","phase":"","title":"Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","status":"AVAILABLE","sponsor":"StemCyte, Inc.","startDate":"","conditions":"Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome","enrollment":""},{"nctId":"NCT07339111","phase":"PHASE3","title":"Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis","status":"RECRUITING","sponsor":"Medipost, Inc.","startDate":"2026-03-11","conditions":"Knee Cartilage Defects","enrollment":300},{"nctId":"NCT03420963","phase":"PHASE1","title":"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-31","conditions":"Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm","enrollment":12},{"nctId":"NCT07101432","phase":"PHASE1","title":"Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-11-04","conditions":"Head and Neck Cancer","enrollment":33},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT03441958","phase":"PHASE1, PHASE2","title":"ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-03-07","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT05092451","phase":"PHASE1, PHASE2","title":"Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-11-01","conditions":"B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML)","enrollment":80},{"nctId":"NCT03835312","phase":"NA","title":"Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2019-02-20","conditions":"Diabetes Mellitus, Type 1, Immunologic Deficiency Syndromes","enrollment":50},{"nctId":"NCT07164560","phase":"PHASE1","title":"Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-04-01","conditions":"Refractory/Recurrent Peripheral T-cell Lymphoma","enrollment":45},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT07467863","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC","enrollment":48},{"nctId":"NCT01962636","phase":"NA","title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-12","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia","enrollment":200},{"nctId":"NCT07468201","phase":"","title":"Development of an Innovative Method to Extract Cord Blood Stem Cells With High Efficiency","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2024-04-10","conditions":"HSCs Extraction","enrollment":12},{"nctId":"NCT06930651","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-03","conditions":"Myeloid Malignancies","enrollment":42},{"nctId":"NCT07134712","phase":"PHASE2","title":"Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II","status":"NOT_YET_RECRUITING","sponsor":"HONYA Medical Co Ltd","startDate":"2026-03-30","conditions":"Acute Myocardial Infarction (AMI)","enrollment":102},{"nctId":"NCT06066359","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-11-30","conditions":"Myeloma","enrollment":44},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT04565665","phase":"PHASE1, PHASE2","title":"Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":70},{"nctId":"NCT07462650","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-01","conditions":"Colorectal Cancer Metastatic, Adenocarcinoma of Colon","enrollment":48},{"nctId":"NCT07454122","phase":"PHASE1","title":"CD5CAR-NK Cells for Refractory Invasive Mold Disease","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2026-05","conditions":"Fungal Infection","enrollment":10},{"nctId":"NCT03541889","phase":"PHASE1","title":"REVEAL Biomarkers of Engraftment After Alternative Donor HSCT","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2021-02-05","conditions":"Primary Graft Failure","enrollment":56},{"nctId":"NCT05703854","phase":"PHASE1, PHASE2","title":"Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-03-29","conditions":"Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma","enrollment":50},{"nctId":"NCT07137481","phase":"PHASE2","title":"Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2027-02-28","conditions":"Hematological Malignancies","enrollment":70},{"nctId":"NCT06947473","phase":"PHASE1, PHASE2","title":"Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-03-18","conditions":"Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension","enrollment":45},{"nctId":"NCT07441967","phase":"PHASE2","title":"The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-20","conditions":"Hematologic Malignancies","enrollment":44},{"nctId":"NCT07441720","phase":"PHASE2","title":"Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2026-02-28","conditions":"Thrombocytopenia, Cancer Treatment-induced Thrombocytopenia","enrollment":25},{"nctId":"NCT06904482","phase":"PHASE2","title":"Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-08-13","conditions":"aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia","enrollment":36},{"nctId":"NCT02730299","phase":"PHASE3","title":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","status":"COMPLETED","sponsor":"Gamida Cell ltd","startDate":"2016-12-16","conditions":"Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)","enrollment":125},{"nctId":"NCT03158896","phase":"PHASE1","title":"Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-07-09","conditions":"Acute Graft Versus Host Disease","enrollment":24},{"nctId":"NCT07273643","phase":"","title":"Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-01-13","conditions":"Intraventricular Hemorrhage, Pulmonary Hemorrhage, Death","enrollment":30},{"nctId":"NCT01366092","phase":"PHASE2","title":"Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-07","conditions":"Chronic Graft-versus-host Disease","enrollment":35},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT05922930","phase":"PHASE1, PHASE2","title":"Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-11","conditions":"Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma","enrollment":51},{"nctId":"NCT07212335","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-10-01","conditions":"Immune Effector Cell Associated Hematotoxicity","enrollment":15},{"nctId":"NCT07295067","phase":"PHASE1","title":"Extracellular Vesicles for the Treatment of Syringomyelia","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-12-23","conditions":"Syringomyelia","enrollment":18},{"nctId":"NCT07304440","phase":"PHASE1, PHASE2","title":"Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study","status":"RECRUITING","sponsor":"Adia Med of Winter Park LLC","startDate":"2026-01-12","conditions":"Autism Spectrum Disorder, Autism, ASD","enrollment":100},{"nctId":"NCT05775718","phase":"PHASE2","title":"Shingrix In Recipients of Allogeneic Transplants","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-10-24","conditions":"Bone Marrow Transplant, Stem Cell Transplant","enrollment":55},{"nctId":"NCT07385326","phase":"NA","title":"Umbilical Cord Clamping Methods and Stem Cell Counts in Preterm Infants","status":"COMPLETED","sponsor":"Era Tufan Benli","startDate":"2015-01","conditions":"Preterm Birth, Umbilical Cord Clamping","enrollment":49},{"nctId":"NCT05110742","phase":"PHASE1, PHASE2","title":"Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-04-22","conditions":"Hematological Malignancy","enrollment":64},{"nctId":"NCT07377526","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-07-01","conditions":"Pancreatic Cancer","enrollment":37},{"nctId":"NCT01733186","phase":"PHASE1, PHASE2","title":"Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects","status":"COMPLETED","sponsor":"Medipost, Inc.","startDate":"2013-01-07","conditions":"Degeneration Articular Cartilage Knee","enrollment":12},{"nctId":"NCT05612919","phase":"NA","title":"Red Blood Cells From Umbilical Cord for Transfusion of Preterm Infants","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2023-09-13","conditions":"Infant, Extremely Premature, Erythrocyte Transfusion, Umbilical Cord Issue","enrollment":41},{"nctId":"NCT06464965","phase":"PHASE1","title":"Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-07-03","conditions":"Gastric Cancer, Pancreas Adenocarcinoma","enrollment":10},{"nctId":"NCT04991870","phase":"PHASE1","title":"Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-28","conditions":"Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma","enrollment":25},{"nctId":"NCT06013423","phase":"PHASE2","title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-07-23","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT05331872","phase":"PHASE1","title":"Umbilical Cord-derived Mesenchymal Stem Cell Infusion in the Management of Adult Liver Cirrhosis","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2021-01-01","conditions":"Liver Cirrhosis","enrollment":20},{"nctId":"NCT06415461","phase":"PHASE1","title":"A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2024-05-10","conditions":"Sacroiliac; Backache, Pain, Back","enrollment":9},{"nctId":"NCT01652092","phase":"NA","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-09-04","conditions":"SCID, Omenn's Syndrome, Reticular Dysgenesis","enrollment":57},{"nctId":"NCT06358430","phase":"PHASE1","title":"Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-12-02","conditions":"Colorectal Cancer, Minimal Residual Disease","enrollment":42},{"nctId":"NCT06500481","phase":"PHASE3","title":"Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-03-04","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":115},{"nctId":"NCT04528355","phase":"","title":"Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2020-08-20","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":50},{"nctId":"NCT00012545","phase":"","title":"Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2001-11-01","conditions":"Sickle Cell Disease, Sickle Cell Trait","enrollment":307},{"nctId":"NCT04943289","phase":"PHASE1","title":"Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Joanne Kurtzberg, MD","startDate":"2021-01-24","conditions":"Primary Progressive Multiple Sclerosis","enrollment":20},{"nctId":"NCT03904134","phase":"NA","title":"Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2019-06-14","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes","enrollment":1753},{"nctId":"NCT06991114","phase":"PHASE2","title":"AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.","status":"RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2025-07-09","conditions":"Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc)","enrollment":90},{"nctId":"NCT07301866","phase":"PHASE1, PHASE2","title":"A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.","status":"RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2025-10-06","conditions":"Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk, Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor","enrollment":7},{"nctId":"NCT03828344","phase":"PHASE1","title":"Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Baylx Inc.","startDate":"2026-12-01","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT07047456","phase":"PHASE3","title":"Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-07-11","conditions":"Acute Graft Versus Host Disease","enrollment":134},{"nctId":"NCT01451502","phase":"NA","title":"Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Lymphatic Diseases, Hematopoietic Malignancy","enrollment":250},{"nctId":"NCT01962415","phase":"PHASE2","title":"Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2014-02-04","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":100},{"nctId":"NCT02184676","phase":"NA","title":"T1D Risk Assessment in Kids With Relatives","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-05-28","conditions":"Type 1 Diabetes","enrollment":512},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT07274059","phase":"EARLY_PHASE1","title":"Allogeneic UCB-derived CAR-T for SLE","status":"RECRUITING","sponsor":"Chengdu Ucello Biotechnology Co., Ltd.","startDate":"2025-03-26","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":48},{"nctId":"NCT06265220","phase":"PHASE1","title":"AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2024-04-03","conditions":"Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus","enrollment":51},{"nctId":"NCT02251821","phase":"PHASE2","title":"JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-10-20","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":61},{"nctId":"NCT06807606","phase":"PHASE2","title":"Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-03","conditions":"Hematologic Malignancies","enrollment":35},{"nctId":"NCT07203599","phase":"PHASE1, PHASE2","title":"A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes","status":"RECRUITING","sponsor":"Shenzhen People's Hospital","startDate":"2025-09-20","conditions":"Androgenic Alopecia","enrollment":59},{"nctId":"NCT06443281","phase":"","title":"Pain Phenotyping in Patients With Neuropathic Pain After Spinal Cord Injury","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2024-04-17","conditions":"Spinal Cord Injuries, Pain, Neuropathic, Nociceptive Pain","enrollment":300},{"nctId":"NCT07256353","phase":"EARLY_PHASE1","title":"Allogeneic UCB-derived CAR-T for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The General Hospital of Western Theater Command","startDate":"2025-12-01","conditions":"B-Cell Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT07253233","phase":"EARLY_PHASE1","title":"Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors","status":"NOT_YET_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-12-01","conditions":"Spinal Cord Injury","enrollment":10},{"nctId":"NCT06534255","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of MegaLT Injection for Treating Refractory Thrombocytopenia Following Radiotherapy, Chemotherapy, or Transplantation.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-12-04","conditions":"Refractory Thrombocytopenia","enrollment":10},{"nctId":"NCT07139509","phase":"PHASE1","title":"Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Xi'an No.3 Hospital","startDate":"2024-10-03","conditions":"Relapsed/Refractory Multiple Myeloma(MM)","enrollment":18},{"nctId":"NCT07227740","phase":"","title":"Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury","status":"RECRUITING","sponsor":"Craig Hospital","startDate":"2025-07-15","conditions":"Spinal Cord Injuries, Endothelial Dysfunction, Testosterone Deficiency","enrollment":48},{"nctId":"NCT01881334","phase":"","title":"Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants","status":"AVAILABLE","sponsor":"Joanne Kurtzberg, MD","startDate":"","conditions":"Hematologic Malignancies, Inborn Errors of Metabolism Disorders, Immune Deficiencies","enrollment":""},{"nctId":"NCT04707300","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-02-16","conditions":"Hematologic Malignancy","enrollment":10},{"nctId":"NCT06707259","phase":"PHASE1","title":"Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-12-01","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT03876821","phase":"","title":"Collect of Cord Blood From Subjects at Risk for Sickle Cell Disease, for the Purpose of Laboratory Research","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-23","conditions":"Sickle Cell Disease","enrollment":44},{"nctId":"NCT07227727","phase":"","title":"Endothelial Dysfunction After SCI","status":"RECRUITING","sponsor":"Craig Hospital","startDate":"2025-07-31","conditions":"Spinal Cord Injuries, Endothelial Dysfunction","enrollment":40},{"nctId":"NCT04744116","phase":"EARLY_PHASE1","title":"Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease","enrollment":24},{"nctId":"NCT02727803","phase":"PHASE2","title":"Personalized NK Cell Therapy in CBT","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-19","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT03913026","phase":"PHASE2","title":"UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2019-04-01","conditions":"High Risk Hematologic Malignancy, Cord Blood Transplant","enrollment":30},{"nctId":"NCT05334329","phase":"PHASE1","title":"Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-07-20","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma","enrollment":6},{"nctId":"NCT06083883","phase":"PHASE1","title":"Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-27","conditions":"Synovial Sarcoma, Myxoid/Round Cell Liposarcoma","enrollment":44},{"nctId":"NCT06066424","phase":"PHASE1","title":"Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-24","conditions":"Solid Tumors","enrollment":54},{"nctId":"NCT03016806","phase":"","title":"Umbilical Cord Blood Transplantation From Unrelated Donors","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2015-06","conditions":"Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder","enrollment":30},{"nctId":"NCT07208344","phase":"EARLY_PHASE1","title":"Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-07-31","conditions":"Alzheimer Disease (AD)","enrollment":30},{"nctId":"NCT07183761","phase":"PHASE2","title":"A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects With Moderate to Severe Diabetic Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Min Long","startDate":"2025-10-01","conditions":"Diabetic Peripheral Neuropathy (DPN)","enrollment":140},{"nctId":"NCT07177456","phase":"EARLY_PHASE1","title":"Study on Safety and Efficacy of UCB-MNCs for Radiation-induced Lung Injury","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-10-01","conditions":"Radiation-induced Lung Injury","enrollment":10},{"nctId":"NCT07175207","phase":"EARLY_PHASE1","title":"Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-10-01","conditions":"Chronic Radiation Induced Intestinal Injury, Chronic Radiation Enteritis","enrollment":10},{"nctId":"NCT06737380","phase":"PHASE1","title":"UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients","status":"RECRUITING","sponsor":"LiveKidney.Bio","startDate":"2025-01-07","conditions":"SLE, Lupus, Systemic Lupus Erthematosus","enrollment":10},{"nctId":"NCT07110090","phase":"PHASE1","title":"Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-28","conditions":"Thrombocytopenia, Cancer","enrollment":16},{"nctId":"NCT02254863","phase":"PHASE1","title":"UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells","status":"RECRUITING","sponsor":"Joanne Kurtzberg, MD","startDate":"2014-09","conditions":"Adrenoleukodystrophy, Batten Disease, Mucopolysaccharidosis II","enrollment":40},{"nctId":"NCT05632484","phase":"NA","title":"Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2023-03-10","conditions":"Hereditary Haemorrhagic Telangiectasia","enrollment":16},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT07131540","phase":"PHASE1","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-01","conditions":"Acute-On-Chronic Liver Failure","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cord Blood Cell","genericName":"Cord Blood Cell","companyName":"China Spinal Cord Injury Network","companyId":"china-spinal-cord-injury-network","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cord blood-derived cells promote neural regeneration and functional recovery in spinal cord injury through cell replacement, neuroprotection, and anti-inflammatory effects. Used for Spinal cord injury.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}